The Embassy Suites San Francisco Airport – South San Francisco hotel is conveniently located 3 miles from San Francisco Airport (SFO) and 10 miles south of downtown San Francisco. Enjoy spacious, contemporary accommodations in this all-suite hotel, where a separate living area and bedroom are standard, and relax or work in a flexible space that has WiFi and convenient, delicious dining options at your fingertips.
The following speakers are presenting at the conference.
Principal Scientist Drug Metabolism and Pharmacokinetics Genentech San Francisco, CA, USA
Dr. Laurent Salphati is currently a Principal Scientist in the Drug Metabolism and Pharmacokinetics department at
Genentech, Inc. He heads the Permeability/Drug Transporters group and has been supporting and leading immunology
and oncology project teams from preclinical discovery to late stage clinical development. He received his Pharm.D.
from the University of Paris XI, France, and conducted his Ph.D research, investigating the complementary roles of
P-glycoprotein and CYP3A in drug absorption and disposition, at the University of California, San Francisco under
the guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics and pharmacodynamics of
drugs (PK/PD and PB/PK modeling) and the roles of drug transporters in drug absorption and disposition.
Vice Chair of the Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA
John D. Schuetz received his Ph.D. in Biochemical Pharmacology/Toxicology (with Robert B. Diasio) from the Medical College of Virginia in Richmond in 1984 and completed his postdoctoral training in Molecular Cancer Biology (with I. David Goldman and Eric H. Westin (a Dr. Robert C. Gallo protégé), and subsequently worked with Dr. Philip Guzelian on CYPs, also at the Medical College of Virginia. In 1992, he joined the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital as an Assistant Member. He was promoted to the rank of Associate Member in 1997 and then to Member in 2005. In 2006, he was appointed Vice Chair of the department and currently holds this position. He has broad research interests in the role of ABC transporters in normal physiology and pathophysiology. His lab’s current studies are elucidating how transporters affect the biology as well as the therapeutic response of medulloblastoma and acute myeloid leukemia. Dr. Schuetz has authored over 154 articles in peer-reviewed journals and contributed several book chapters. Dr. Schuetz has been elected to the AAAS Electorate nominating committee, elected Chair of the Toxicology Division of American Society for Pharmacology and Experimental Therapeutics (ASPET), Councilor to ASPET and is currently serving as Past-President of ASPET. Further, he was nominated to membership in the ASBMB. He has also been a permanent member of the NIH DMP study section (2002-2007) and contributed service as an Ad hoc member on multiple other national and international grant review panels. Moreover, he is an Associate Editor for the journal Drug Metabolism and Disposition and serves on the editorial board of other peer-reviewed journals (e.g., Scientific Reports, The FASEB Journal).
Senior Principal Scientist, Department of Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Inc. Groton, CT, USA
Dr. Manthena Varma, PhD is Associate Research Fellow, at Pfizer Inc. Dr. Varma received his B. Pharm. degree from the Kakatiya University, India in 2000, and an M.S. degree (2002) and PhD in Pharmaceutics (2005), from the National Institute of Pharmaceutical Education and research (NIPER), Punjab, India. Later, Dr. Varma worked as a Post Doctoral Fellow at the Department of Pharmaceutics, University of Minnesota (Minneapolis). In 2008, he joined Worldwide R&D, Pfizer, Groton, CT. Dr. Varma holds an Adjunct faculty position in the Department of Pharmacy of the University of Rhode Island. Manthena is a founding member and Instructor for a three-day Annual workshop on “Transporters in Drug Discovery and Development: Driving Knowledge from Laboratory to Label” at University of Rhode Island. He is member and ex-chair (2017-18) of North Jersey Drug Metabolism Discussion Group. His research is focused in the fields of ADME/PK technologies and strategies in drug design and development, role of drug transporters and transporter-enzyme interplay (extended clearance) in ADME/PK, clinical pharmacokinetics and DDI predictions/evaluation via mechanistic (PBPK) modeling. He published over 110 original articles/reviews/book chapters and presented over 60 presentations at the scientific conferences in these scientific areas.
6-7 October: “Meet the Experts: Transporter Conference – San Francisco 2014”
You can access the presentations by clicking on the individual speakers, or by navigating to this page. Please note that you must be logged in to see the content.
|Introduction||Péter Krajcsi, SOLVO|
|Transporters in Drug Discovery and Development: Challenges and Opportunities||Harma Ellens, GSK|
|Intestinal transporters, role in absorption||Dhiren R. Thakker,UNC Eshelman School of Pharmacy|
|Prodrugs, Intestinal Uptake Transporter||Ashim K. Mitra, University of Missouri-Kansas City|
|Hepatic uptake transporters IVIVE and DDI predictions.||Manthena Varma, Pfizer|
|In Vivo Models to Bridge the Translational Gaps in Transporter-Mediated PK and DDIs||Maciej Zamek-Gliszczynski, GSK|
|Efflux Transporters in the BBB: Role of Pgp and BCRP in CNS Drug Delivery||William F. Elmquist, University of Minnesota|
|Stem cell derived BBB models||Ethan Lippmann, Wisconsin Institute for Discovery|
|Optimizing compounds for brain penetration- Studies with PI3K inhibitors||Laurent Salphati, Genentech|
|Renal transporters – Roles in elimination and pharmacology||Adrian S Ray, Gilead|
|Lessons in cellular homeostasis of physiological molecules: the role of ABCG2 and ABCC4||John D. Schuetz, St. Jude Children's Research Hospital|
|Disease, toxicity, drug resistance|
|Regulation of Drug Transporters in Infection and Disease; Impact on Drug Disposition||Micheline Piquette-Miller, University of Toronto|
|Regulation of Drug Transporters in HIV-1 Associated Brain Inflammation||Reina Bendayan, University of Toronto|
|Drug susceptibility and toxicity - uptake transporters||Alex Sparreboom, St. Jude Children's Research Hospital|
|Renal Urate Transport: Overview and Role of URAT1||Philip K. Tan, PhD, Principal Scientist, Ardea Biosciences|
|Clinically significant transporter polymorphisms||Kathleen M Giacomini, UCSF|
|The BDDCS||Leslie Z Benet, UCSF|
|Utility of an Integrative System: Sandwich-Cultured Hepatocytes||Kenneth R. Brouwer, Qualyst Transporter Solutions|
|Human physiome on a chip||Murat Cirit, MIT|
|Transgenic and tissue humanized animal models to study membrane transporters||Amar Thyagarajan, Taconic|
|Closing Remarks for the Conference||Péter Krajcsi, SOLVO|